A Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Overview
- Phase
- Phase 3
- Intervention
- Brivaracetam Film-coated tablet
- Conditions
- Childhood Absence Epilepsy
- Sponsor
- UCB Biopharma SRL
- Enrollment
- 84
- Locations
- 24
- Primary Endpoint
- Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
- Status
- Completed
- Last Updated
- 6 months ago
Overview
Brief Summary
The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants who previously participated in N01269 (NCT04666610) and qualify for entry into EP0132 as per N01269 (NCT04666610) protocol with a confirmed diagnosis of childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE), and for whom a reasonable benefit from long-term administration of brivaracetam (BRV) is expected, in the opinion of the Investigator
- •A sexually active male study participant must agree to use contraception during the treatment period and for at least 2 days, corresponding to the time needed to eliminate study treatment, after the last dose of study treatment and refrain from donating sperm during this period
- •A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
- •The study participant is premenarchal OR
- •A woman of childbearing potential (WOCBP) who agrees to follow the contraceptive guidance during the treatment period and for at least 2 days after the last dose of study medication, corresponding to the time needed to eliminate study treatment
- •Study participant is capable of and provides consent/assent, and the study participant's parent/legal representative/caregiver provides signed informed consent for minor study participants, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
Exclusion Criteria
- •Study participant has a history or presence of paroxysmal nonepileptic seizures
- •Study participant has severe medical, neurological, or psychiatric disorders or laboratory values, which could, at the discretion of the Investigator, affect safe participation in the study or would preclude appropriate study participation
- •Study participant has a clinically relevant electrocardiogram (ECG) abnormality in the opinion of the Principal Investigator
- •Study participant has hepatic impairment (Child Pugh Score A, B, or C) based on the Investigator's assessment
- •Study participant has active suicidal ideation prior to study entry as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia Suicide Severity Rating Scale (C-SSRS) (for study participants 6 years or older) or clinical judgment (for study participants younger than 6 years). The study participant should be referred immediately to a Mental Healthcare Professional
- •Study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt). The Investigator must immediately refer the study participant to a Mental Healthcare Professional
- •Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study
- •Participant has a known fructose intolerance or known hypersensitivity to any components of brivaracetam (BRV) or excipients or a drug with similar chemical structure. Note that the tablets contain lactose
- •Study participant has end-stage kidney disease requiring dialysis
- •Concomitant use of carbamazepine, felbamate, gabapentin, oxcarbazepine, phenobarbital, phenytoin, tiagabine, or vigabatrin
Arms & Interventions
Brivaracetam arm
Subjects in this arm will receive various brivaracetam doses as oral solution or film-coated tablet twice per day.
Intervention: Brivaracetam Film-coated tablet
Brivaracetam arm
Subjects in this arm will receive various brivaracetam doses as oral solution or film-coated tablet twice per day.
Intervention: Brivaracetam oral solution
Outcomes
Primary Outcomes
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Time Frame: From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV.
Percentage of Participants With TEAEs Leading to Discontinuation of Study Treatment
Time Frame: From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. TEAEs are defined as AEs that had onset on or after the day of first dose of BRV. Percentage of participants with TEAEs leading to discontinuation were reported.
Secondary Outcomes
- Percentage of Participants With Serious TEAEs(From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months)
- Percentage of Participants With Study Drug-related TEAEs(From Entry Visit up to 16.32 months (median); min, max exposure to BRV was (0.4, 31.0) months)
- Percentage of Participants With Absence Seizure Freedom Within 4 Days Prior to or During the 1-hour Electroencephalogram (EEG)(Full Evaluation Visit (6 months), Yearly Evaluation Visit (12 months), Full Evaluation Visit (18 months), Yearly Evaluation Visit (24 months))
- Percentage of Participants With Absence Seizure Freedom Based on Daily Seizure Diary Over the Entire Evaluation Period and by 3-month Time Intervals(Months 1-3, Months 4-6, Months 7-9, Months 10-12, Months 13-15, Months 16-18, Months 19-21, Months 22-24 and Entire Evaluation Period (Up to 24 months))